At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
BCDA BioCardia
Post-Mkt 10-23 17:49:16 EDT
0.9210
-0.0077
-0.83%
盘后0.9276
+0.0066+0.72%
16:29 EDT
High0.9499Low0.9119Vol40.28K
Open0.9477D1 Closing0.9287Amplitude4.09%
Mkt Cap13.94MTradable Cap11.16MTotal Shares15.14M
T/O37.45KT/O Rate0.33%Tradable Shares12.12M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

BioCardia President and CEO Peter Altman Reports Acquisition of $475 in Common Shares
Reuters  ·  10-21
BioCardia President and CEO Peter Altman Reports Acquisition of $475 in Common Shares
BioCardia announces FDA acceptance of Helix pre-submission package
TIPRANKS  ·  10-19
BioCardia announces FDA acceptance of Helix pre-submission package
BioCardia Announces FDA Acceptance of De Novo Pre-Submission Package for Helix™ Catheter Marketing Clearance FDA Substantive Review and Meeting Expected This Quarter
THOMSON REUTERS  ·  10-19
BioCardia Announces FDA Acceptance of De Novo Pre-Submission Package for Helix™ Catheter Marketing Clearance FDA Substantive Review and Meeting Expected This Quarter
BioCardia Announces FDA Acceptance of De Novo Pre-Submission Package for Helix™ Catheter Marketing Clearance FDA Substantive Review and Meeting Expected this Quarter
GlobeNewswire  ·  10-19
BioCardia Announces FDA Acceptance of De Novo Pre-Submission Package for Helix™ Catheter Marketing Clearance FDA Substantive Review and Meeting Expected this Quarter
BioCardia Outlines Design of CardiAMP HF II Heart Failure Trial at HFSA 2026 Meeting
Reuters  ·  10-07
BioCardia Outlines Design of CardiAMP HF II Heart Failure Trial at HFSA 2026 Meeting
BioCardia Files Revised FDA De Novo Pre-Submission for Helix Catheter Clearance
Reuters  ·  10-01
BioCardia Files Revised FDA De Novo Pre-Submission for Helix Catheter Clearance
BioCardia Files Revised De Novo Pre-Submission for FDA Approval of Helix™ Catheter
THOMSON REUTERS  ·  10-01
BioCardia Files Revised De Novo Pre-Submission for FDA Approval of Helix™ Catheter
BioCardia - FDA Targets Initial Review Within 15 Days and Feedback or Meeting Within 70 Days
THOMSON REUTERS  ·  10-01
BioCardia - FDA Targets Initial Review Within 15 Days and Feedback or Meeting Within 70 Days
BioCardia - FDA Raises no Concerns Regarding Helix Safety Data or Device Performance
THOMSON REUTERS  ·  10-01
BioCardia - FDA Raises no Concerns Regarding Helix Safety Data or Device Performance
BioCardia CEO Peter Altman Acquires $1,030 in Common Shares
Reuters  ·  10-01
BioCardia CEO Peter Altman Acquires $1,030 in Common Shares
BioCardia CEO Peter Altman Acquires Common Shares Worth $1,995
Reuters  ·  09-24
BioCardia CEO Peter Altman Acquires Common Shares Worth $1,995
BioCardia Confirms Timing and Provides Update on FDA Helix Pre-Submission and Pmda Cardiamp HF Shonin Submission
THOMSON REUTERS  ·  09-23
BioCardia Confirms Timing and Provides Update on FDA Helix Pre-Submission and Pmda Cardiamp HF Shonin Submission
BioCardia - to Submit Shonin Pre-Market Application to Pmda in Q4 2026
THOMSON REUTERS  ·  09-23
BioCardia - to Submit Shonin Pre-Market Application to Pmda in Q4 2026
BioCardia - Market Clearance for Cardiamp in Japan Possible by Q4 2027
THOMSON REUTERS  ·  09-23
BioCardia - Market Clearance for Cardiamp in Japan Possible by Q4 2027
BioCardia - to Submit De Novo Pre-Submission for Helix Cathter System to FDA This Quarter
THOMSON REUTERS  ·  09-23
BioCardia - to Submit De Novo Pre-Submission for Helix Cathter System to FDA This Quarter
BioCardia CEO Peter Altman Presents at H.C. Wainwright Global Investment Conference
Reuters  ·  09-10
BioCardia CEO Peter Altman Presents at H.C. Wainwright Global Investment Conference
BioCardia CEO Peter Altman Buys 800 Shares for $872
Reuters  ·  09-05
BioCardia CEO Peter Altman Buys 800 Shares for $872
BioCardia Price Target Maintained with a $25.00/Share by HC Wainwright & Co.
Dow Jones  ·  08-25
BioCardia Price Target Maintained with a $25.00/Share by HC Wainwright & Co.
BioCardia: Advancing Regulatory Momentum in Helix Catheter and CardiAMP HF Programs Supports Buy Rating and Unchanged $25 Price Target
TIPRANKS  ·  08-24
BioCardia: Advancing Regulatory Momentum in Helix Catheter and CardiAMP HF Programs Supports Buy Rating and Unchanged $25 Price Target
BioCardia gets FDA confirmation of Helix meeting minutes
TIPRANKS  ·  08-24
BioCardia gets FDA confirmation of Helix meeting minutes

Introduction

Company Name.
BioCardia
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
BioCardia, Inc., a clinical-stage regenerative medicine company, engages in development of cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP, an autologous mononuclear cell therapy system for the treatment of heart failure and chronic myocardial ischemia; and allogeneic cell therapy for cardiac and pulmonary disease. The company is also developing allogeneic cells therapeutic platform, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic heart failure. In addition, it offers the Helix biotherapeutic delivery system that delivers therapeutics into the heart muscle with a penetrating helical needle from within the heart; and Morph deflectable guides and sheaths. The company is based in Sunnyvale, California.
Issue price:
--